Valuation: Atossa Therapeutics, Inc.

Market Cap 26.45M 23.6M 21.94M 19.96M 37.54M 2.5B 38.22M 264M 103M 1.31B 99.24M 97.14M 4.18B P/E 2026 *
-0.71x
P/E 2027 * -0.95x
Enterprise Value 26.45M 23.6M 21.94M 19.96M 37.54M 2.5B 38.22M 264M 103M 1.31B 99.24M 97.14M 4.18B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-4.68%
1 week+9.50%
Current month+35.90%
1 month+11.81%
3 months+8.61%
6 months-53.83%
Current year-70.06%
1 week 2.3
Extreme 2.3
3.12
1 month 1.82
Extreme 1.82
3.12
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
15.45
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
44.65
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 Free

Director

10,000 0.1161%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-4.68%+9.50%-83.17%-73.24% 26.45M
+0.21%-4.63%+55.34%+71.32% 68.98B
+1.66%+7.51%+8.12%+60.04% 53.15B
+3.14%+7.17%+12.48%+44.42% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
+2.01%-7.86%+35.35%+1.27% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.30%+2.35%+35.99%+81.39% 37.97B
Weighted average by Cap. +1.92%+2.33%+51.46%+103.66%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.5M -29.28M -26.63M -50.11M -3.34B -51.01M -352M -138M -1.74B -132M -130M -5.58B -38.03M -33.94M -31.55M -28.69M -53.98M -3.6B -54.96M -379M -148M -1.88B -143M -140M -6.01B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-10-15 US$2.650 -4.68% 227,027
26-10-14 US$2.780 +8.59% 238,706
26-10-13 US$2.560 +7.17% 71,414
26-10-12 US$2.389 -2.10% 81,419
26-10-09 US$2.440 +0.83% 265,612
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.650USD
Average target price
19.00USD
Spread / Average Target
+616.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock